Method for enhancing production of isoprenoid compounds
View Patent ↗The present invention provides methods of producing an isoprenoid or an isoprenoid precursor in a genetically modified host cell. The methods generally involve modulating the level of hydroxymethylglutaryl-CoA (HMG-CoA) in the cell, such that the level of HMG-CoA is not toxic to the cell and/or does not substantially inhibit cell growth, but is maintained at a level that provides for high-level production of mevalonate, IPP, and other downstream products of an isoprenoid or isoprenoid pathway, e.g., polyprenyl diphosphates and isoprenoid compounds. The present invention further provides genetically modified host cells that are suitable for use in a subject method. The present invention further provides recombinant nucleic acid constructs for use in generating a subject genetically modified host cell, including recombinant nucleic acid constructs comprising nucleotide sequences encoding one or more mevalonate pathway enzymes, and recombinant vectors (e.g., recombinant expression vectors) comprising same. The present invention further provides methods for identifying nucleic acids that encode HMG-CoA reductase (HMGR) variants that provide for relief of HMG-CoA accumulation-induced toxicity. The present invention farther provides methods for identifying agents that reduce intracellular accumulation of HMG-CoA.
1. A genetically modified host cell that produces an isoprenoid or isoprenoid precursor,
wherein the genetically modified host cell is a prokaryotic host cell that does not normally produce isopentenyl pyrophosphate via a mevalonate pathway, wherein the genetically modified host cell is genetically modified with one or more heterologous nucleic acids comprising nucleotide sequences encoding:
i) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA (HMGS);
ii) an enzyme that converts HMG-CoA to mevalonate (HMGR);
iii) an enzyme that converts mevalonate to mevalonate 5-phosphate;
iv) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and
v) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate,
wherein the ratio of HMGR activity to HMGS activity in the cell is at least 1, and wherein the copy number of HMGR- and HMGS-encoding nucleotide sequences in the cell is higher than in a cell in which HMGR and HMGS are encoded on a low copy number pBAD33 plasmid and operably linked to an arabinose inducible P LAC promoter, such that the level of HMG-CoA present in the cell is not toxic to the cell and/or does not substantially inhibit growth of the cell.
2. The genetically modified host cell of claim 1 , wherein the host cell is an Escherichia coli strain.
3. The genetically modified host cell of claim 1 , wherein the genetically modified host cell further comprises an acetoacetyl-CoA thiolase that is heterologous to the genetically modified host cell.
4. The genetically modified host cell of claim 1 , wherein the genetically modified host cell comprises two or more copies of a heterologous nucleic acid comprising a nucleotide sequence encoding the HMGR.
5. The genetically modified host cell of claim 1 , wherein the level of isoprenoid or isoprenoid precursor produced in the genetically modified host cell is higher than the level of isoprenoid or isoprenoid precursor produced in a control host cell.
6. The genetically modified host cell of claim 1 , wherein the heterologous nucleic acid comprising a nucleotide sequence encoding HMGR is a medium copy number plasmid, and wherein the heterologous nucleic acid comprising a nucleotide sequence encoding HMGS is a low copy number plasmid.
7. The genetically modified host cell of claim 1 , wherein the heterologous nucleic acid comprising a nucleotide sequence encoding HMGR is a high copy number plasmid, and wherein the heterologous nucleic acid comprising a nucleotide sequence encoding HMGS is a medium copy number plasmid.
8. The genetically modified host cell of claim 1 , wherein the heterologous nucleic acid comprising a nucleotide sequence encoding HMGR is a high copy number plasmid, and wherein the heterologous nucleic acid comprising a nucleotide sequence encoding HMGS is a low copy number plasmid.
9. The genetically modified host cell of claim 1 , wherein the one or more heterologous nucleic acids comprising nucleotide sequences encoding HMGS and HMGR are integrated into the genome of the host cell.
10. The genetically modified host cell of claim 1 , wherein the genetically modified host cell is genetically modified with a heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous acetoacetyl-CoA thiolase.
11. The genetically modified host cell of claim 1 , wherein the genetically modified host cell is further genetically modified such that an endogenous 1-deoxy-D-xylulose 5-diphosphate (DXP) biosynthetic pathway gene is functionally disabled by deletion of all or part of a DXP pathway gene, such that the DXP pathway gene product is not made.
12. The genetically modified host cell of claim 1 , wherein the HMGS, the HMGR, the enzyme that converts mevalonate to mevalonate 5-phosphate, the enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate, and the enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate are eukaryotic enzymes.
13. The genetically modified host cell of claim 12 , wherein the HMGS, HMGR, the enzyme that converts mevalonate to mevalonate 5-phosphate, the enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate, and the enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate, are yeast enzymes.
14. The genetically modified host cell of claim 1 , wherein the HMGR coding region is under control of a stronger promoter than the HMGS coding region.
15. The genetically modified host cell of claim 1 , wherein the host cell is Bacillus subtilis, Pseudomonas pudita, Pseudomonas aeruginosa, Pseudomonas mevalonii, Rhodobacter sphaero ides, Rhodobacter capsulatus, Rhodospirillum Rubrum , or a Rhodococcus sp.
16. A genetically modified Escherichia coli host cell that produces an isoprenoid or isoprenoid precursor,
wherein the genetically modified E. coli host cell is genetically modified with one or more heterologous nucleic acids comprising nucleotide sequences encoding:
i) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA (HMGS);
ii) an enzyme that converts HMG-CoA to mevalonate (HMGR);
iii) an enzyme that converts mevalonate to mevalonate 5-phosphate;
iv) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and
v) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate,
wherein the ratio of HMGR activity to HMGS activity in the cell is at least 1, and wherein the copy number of HMGR- and HMGS-encoding nucleotide sequences in the cell is higher than in a cell in which HMGR and HMGS are encoded on a low copy number pBAD33 plasmid and operably linked to an arabinose inducible P LAC promoter,
such that the level of HMG-CoA present in the cell is not toxic to the cell and/or does not substantially inhibit growth of the cell.